Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1999 Aug;54(8):742–746. doi: 10.1136/thx.54.8.742

A clinical approach to the use of methotrexate for sarcoidosis

R Baughman 1, E Lower 1
PMCID: PMC1745538  PMID: 10413729

Full Text

The Full Text of this article is available as a PDF (90.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agbogu B. N., Stern B. J., Sewell C., Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995 Sep;52(9):875–879. doi: 10.1001/archneur.1995.00540330053014. [DOI] [PubMed] [Google Scholar]
  2. Andersen P. A., West S. G., O'Dell J. R., Via C. S., Claypool R. G., Kotzin B. L. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med. 1985 Oct;103(4):489–496. doi: 10.7326/0003-4819-103-4-489. [DOI] [PubMed] [Google Scholar]
  3. Bailin P. L., Tindall J. P., Roenigk H. H., Jr, Hogan M. D. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA. 1975 Apr 28;232(4):359–362. [PubMed] [Google Scholar]
  4. Baughman R. P., Lower E. E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997 Sep;14(2):121–130. [PubMed] [Google Scholar]
  5. Baughman R. P., Lower E. E. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med. 1997 Dec;18(4):853–864. doi: 10.1016/s0272-5231(05)70423-8. [DOI] [PubMed] [Google Scholar]
  6. Baughman R. P., Lower E. E. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1268–1271. doi: 10.1164/ajrccm/142.6_Pt_1.1268. [DOI] [PubMed] [Google Scholar]
  7. Baughman R. P., Strohofer S. A., Buchsbaum J., Lower E. E. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 1990 Jan;115(1):36–42. [PubMed] [Google Scholar]
  8. Baughman R. P., Winget D. B., Bowen E. H., Lower E. E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997 Sep;14(2):154–158. [PubMed] [Google Scholar]
  9. Chittock D. R., Joseph M. G., Paterson N. A., McFadden R. G. Necrotizing sarcoid granulomatosis with pleural involvement. Clinical and radiographic features. Chest. 1994 Sep;106(3):672–676. doi: 10.1378/chest.106.3.672. [DOI] [PubMed] [Google Scholar]
  10. Feagan B. G. Methotrexate therapy for chronic sarcoidosis: is the therapeutic index acceptable? J Pediatr. 1997 Jan;130(1):3–4. [PubMed] [Google Scholar]
  11. Fenton D. A., Shaw M., Black M. M. Invasive nasal sarcoidosis treated with methotrexate. Clin Exp Dermatol. 1985 May;10(3):279–283. doi: 10.1111/j.1365-2230.1985.tb00571.x. [DOI] [PubMed] [Google Scholar]
  12. Gedalia A., Molina J. F., Ellis G. S., Jr, Galen W., Moore C., Espinoza L. R. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997 Jan;130(1):25–29. doi: 10.1016/s0022-3476(97)70306-8. [DOI] [PubMed] [Google Scholar]
  13. Gibson G. J., Prescott R. J., Muers M. F., Middleton W. G., Mitchell D. N., Connolly C. K., Harrison B. D. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996 Mar;51(3):238–247. doi: 10.1136/thx.51.3.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gideon N. M., Mannino D. M. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med. 1996 Apr;100(4):423–427. doi: 10.1016/S0002-9343(97)89518-6. [DOI] [PubMed] [Google Scholar]
  15. Gottlieb J. E., Israel H. L., Steiner R. M., Triolo J., Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997 Mar;111(3):623–631. doi: 10.1378/chest.111.3.623. [DOI] [PubMed] [Google Scholar]
  16. Hargreaves M. R., Mowat A. G., Benson M. K. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992 Aug;47(8):628–633. doi: 10.1136/thx.47.8.628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Henderson C. A., Ilchyshyn A., Curry A. R. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med. 1994 Oct;87(10):632–633. [PMC free article] [PubMed] [Google Scholar]
  18. Hunninghake G. W., Crystal R. G. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med. 1981 Aug 20;305(8):429–434. doi: 10.1056/NEJM198108203050804. [DOI] [PubMed] [Google Scholar]
  19. Hunninghake G. W., Gilbert S., Pueringer R., Dayton C., Floerchinger C., Helmers R., Merchant R., Wilson J., Galvin J., Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994 Apr;149(4 Pt 1):893–898. doi: 10.1164/ajrccm.149.4.8143052. [DOI] [PubMed] [Google Scholar]
  20. Israel H. L., Fouts D. W., Beggs R. A. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973 Apr;107(4):609–614. doi: 10.1164/arrd.1973.107.4.609. [DOI] [PubMed] [Google Scholar]
  21. Israel H. L. The treatment of sarcoidosis. Postgrad Med J. 1970 Aug;46(538):537–540. doi: 10.1136/pgmj.46.538.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jones G., Mierins E., Karsh J. Methotrexate-induced asthma. Am Rev Respir Dis. 1991 Jan;143(1):179–181. doi: 10.1164/ajrccm/143.1.179. [DOI] [PubMed] [Google Scholar]
  23. Kaye O., Palazzo E., Grossin M., Bourgeois P., Kahn M. F., Malaise M. G. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol. 1995 Jul;34(7):642–644. doi: 10.1093/rheumatology/34.7.642. [DOI] [PubMed] [Google Scholar]
  24. Knox T. A., Kaplan M. M., Gelfand J. A., Wolff S. M. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med. 1995 Apr 15;122(8):592–595. doi: 10.7326/0003-4819-122-8-199504150-00006. [DOI] [PubMed] [Google Scholar]
  25. Kremer J. M., Alarcón G. S., Lightfoot R. W., Jr, Willkens R. F., Furst D. E., Williams H. J., Dent P. B., Weinblatt M. E. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994 Mar;37(3):316–328. doi: 10.1002/art.1780370304. [DOI] [PubMed] [Google Scholar]
  26. Kremer J. M., Lee J. K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986 Jul;29(7):822–831. doi: 10.1002/art.1780290702. [DOI] [PubMed] [Google Scholar]
  27. Lacher M. J. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med. 1968 Dec;69(6):1247–1248. doi: 10.7326/0003-4819-69-6-1247. [DOI] [PubMed] [Google Scholar]
  28. Lennarson P., Barney N. P. Interstitial keratitis as presenting ophthalmic sign of sarcoidosis in a child. J Pediatr Ophthalmol Strabismus. 1995 May-Jun;32(3):194–196. doi: 10.3928/0191-3913-19950501-15. [DOI] [PubMed] [Google Scholar]
  29. Lower E. E., Baughman R. P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr 24;155(8):846–851. [PubMed] [Google Scholar]
  30. Lower E. E., Baughman R. P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci. 1990 Mar;299(3):153–157. doi: 10.1097/00000441-199003000-00002. [DOI] [PubMed] [Google Scholar]
  31. Lower E. E., Broderick J. P., Brott T. G., Baughman R. P. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997 Sep 8;157(16):1864–1868. [PubMed] [Google Scholar]
  32. Lower E. E., Smith J. T., Martelo O. J., Baughman R. P. The anemia of sarcoidosis. Sarcoidosis. 1988 Mar;5(1):51–55. [PubMed] [Google Scholar]
  33. Lynch J. P., 3rd, McCune W. J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med. 1997 Feb;155(2):395–420. doi: 10.1164/ajrccm.155.2.9032171. [DOI] [PubMed] [Google Scholar]
  34. MAYOCK R. L., BERTRAND P., MORRISON C. E., SCOTT J. H. MANIFESTATIONS OF SARCOIDOSIS. ANALYSIS OF 145 PATIENTS, WITH A REVIEW OF NINE SERIES SELECTED FROM THE LITERATURE. Am J Med. 1963 Jul;35:67–89. doi: 10.1016/0002-9343(63)90165-7. [DOI] [PubMed] [Google Scholar]
  35. Morgan S. L., Baggott J. E., Vaughn W. H., Austin J. S., Veitch T. A., Lee J. Y., Koopman W. J., Krumdieck C. L., Alarcón G. S. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994 Dec 1;121(11):833–841. doi: 10.7326/0003-4819-121-11-199412010-00002. [DOI] [PubMed] [Google Scholar]
  36. Neville E., Walker A. N., James D. G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983 Autumn;52(208):525–533. [PubMed] [Google Scholar]
  37. Nyfors A., Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica. 1983;167(5):260–261. doi: 10.1159/000249793. [DOI] [PubMed] [Google Scholar]
  38. Pia G., Pascalis L., Aresu G., Rosetti L., Ledda M. A. Evaluation of the efficacy and toxicity of the cyclosporine A-flucortolone-methotrexate combination in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1996 Sep;13(2):146–152. [PubMed] [Google Scholar]
  39. Pueringer R. J., Schwartz D. A., Dayton C. S., Gilbert S. R., Hunninghake G. W. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest. 1993 Mar;103(3):832–838. doi: 10.1378/chest.103.3.832. [DOI] [PubMed] [Google Scholar]
  40. Rizzato G., Fraioli P., Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax. 1995 May;50(5):555–559. doi: 10.1136/thx.50.5.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rizzato G., Montemurro L., Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis. 1998 Mar;15(1):52–58. [PubMed] [Google Scholar]
  42. Rosenfeld A. A. Sexual abuse of children. JAMA. 1978 Jul 7;240(1):43–43. [PubMed] [Google Scholar]
  43. Rustin G. J., Rustin F., Dent J., Booth M., Salt S., Bagshawe K. D. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med. 1983 Mar 3;308(9):473–476. doi: 10.1056/NEJM198303033080901. [DOI] [PubMed] [Google Scholar]
  44. SCADDING J. G. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961 Nov 4;2(5261):1165–1172. doi: 10.1136/bmj.2.5261.1165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Soriano F. G., Caramelli P., Nitrini R., Rocha A. S. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad Med J. 1990 Feb;66(772):142–143. doi: 10.1136/pgmj.66.772.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sostman H. D., Matthay R. A., Putman C. E., Smith G. J. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976 Sep;55(5):371–388. doi: 10.1097/00005792-197609000-00002. [DOI] [PubMed] [Google Scholar]
  47. Thomas P. D., Hunninghake G. W. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis. 1987 Mar;135(3):747–760. doi: 10.1164/arrd.1987.135.3.747. [DOI] [PubMed] [Google Scholar]
  48. Tolman K. G., Clegg D. O., Lee R. G., Ward J. R. Methotrexate and the liver. J Rheumatol Suppl. 1985 Dec;12 (Suppl 12):29–34. [PubMed] [Google Scholar]
  49. Veien N. K., Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol. 1977 Aug;97(2):213–216. doi: 10.1111/j.1365-2133.1977.tb15068.x. [DOI] [PubMed] [Google Scholar]
  50. Wallace C. A., Smith A. L., Sherry D. D. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol. 1993 Oct;20(10):1764–1768. [PubMed] [Google Scholar]
  51. Webster G. F., Razsi L. K., Sanchez M., Shupack J. L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991 Mar;24(3):451–454. doi: 10.1016/0190-9622(91)70071-9. [DOI] [PubMed] [Google Scholar]
  52. White D. A., Rankin J. A., Stover D. E., Gellene R. A., Gupta S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis. 1989 Jan;139(1):18–21. doi: 10.1164/ajrccm/139.1.18. [DOI] [PubMed] [Google Scholar]
  53. Williams H. J., Willkens R. F., Samuelson C. O., Jr, Alarcón G. S., Guttadauria M., Yarboro C., Polisson R. P., Weiner S. R., Luggen M. E., Billingsley L. M. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985 Jul;28(7):721–730. doi: 10.1002/art.1780280702. [DOI] [PubMed] [Google Scholar]
  54. van de Kerkhof P. C., Hoefnagels W. H., van Haelst U. J., Mali J. W. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol. 1985 May;10(3):194–200. doi: 10.1111/j.1365-2230.1985.tb00558.x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES